NYSE:ZYME - Zymeworks Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.90 -0.23 (-1.43 %) (As of 01/18/2019 04:00 PM ET)Previous Close$15.90Today's Range$15.82 - $16.7052-Week Range$9.57 - $29.00Volume153,174 shsAverage Volume178,745 shsMarket Capitalization$515.80 millionP/E Ratio-27.89Dividend YieldN/ABeta1.76 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that can two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright in 2003 and is headquartered in Vancouver, Canada. Receive ZYME News and Ratings via Email Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A Webwww.zymeworks.com Phone604-678-1388Debt Debt-to-Equity RatioN/A Current Ratio6.42 Quick Ratio6.42Price-To-Earnings Trailing P/E Ratio-27.89 Forward P/E Ratio-7.04 P/E GrowthN/A Sales & Book Value Annual Sales$51.76 million Price / Sales9.82 Cash FlowN/A Price / Cash FlowN/A Book Value$4.59 per share Price / Book3.46Profitability EPS (Most Recent Fiscal Year)($0.57) Net Income$-10,400,000.00 Net Margins-17.66% Return on Equity-9.24% Return on Assets-8.05%Miscellaneous Employees147 Outstanding Shares31,980,000Market Cap$515.80 million OptionableOptionable Zymeworks (NYSE:ZYME) Frequently Asked Questions What is Zymeworks' stock symbol? Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME." How were Zymeworks' earnings last quarter? Zymeworks Inc (NYSE:ZYME) issued its earnings results on Tuesday, November, 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.67) by $0.08. The company had revenue of $2.05 million for the quarter, compared to analysts' expectations of $2 million. Zymeworks had a negative net margin of 17.66% and a negative return on equity of 9.24%. View Zymeworks' Earnings History. When is Zymeworks' next earnings date? Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Zymeworks. What price target have analysts set for ZYME? 6 analysts have issued 12-month target prices for Zymeworks' stock. Their predictions range from $15.00 to $37.00. On average, they anticipate Zymeworks' stock price to reach $24.3333 in the next year. This suggests a possible upside of 53.0% from the stock's current price. View Analyst Price Targets for Zymeworks. What is the consensus analysts' recommendation for Zymeworks? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks. Has Zymeworks been receiving favorable news coverage? Media headlines about ZYME stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zymeworks earned a news impact score of 0.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next several days. Who are some of Zymeworks' key competitors? Some companies that are related to Zymeworks include Ironwood Pharmaceuticals (IRWD), Endocyte (ECYT), Innoviva (INVA), AnaptysBio (ANAB), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), Myokardia (MYOK), Zogenix (ZGNX), Allakos (ALLK), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), Portola Pharmaceuticals (PTLA) and Mallinckrodt (MNK). Who are Zymeworks' key executives? Zymeworks' management team includes the folowing people: Ali Tehrani, President, Chief Executive Officer & DirectorNeil Klompas, Chief Financial OfficerDiana F. Hausman, Chief Medical OfficerAnthony J. Polverino, Chief Scientific Officer & VP-Early DevelopmentSurjit Bhimarao Dixit, Vice President-Technology When did Zymeworks IPO? (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager. How do I buy shares of Zymeworks? Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zymeworks' stock price today? One share of ZYME stock can currently be purchased for approximately $15.90. How big of a company is Zymeworks? Zymeworks has a market capitalization of $515.80 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe. What is Zymeworks' official website? The official website for Zymeworks is http://www.zymeworks.com. How can I contact Zymeworks? Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected] MarketBeat Community Rating for Zymeworks (NYSE ZYME)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 137 (Vote Outperform)Underperform Votes: 110 (Vote Underperform)Total Votes: 247MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: What is a balanced fund?